Shaker Investments LLC OH Cuts Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Shaker Investments LLC OH reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 92.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 755 shares of the company’s stock after selling 9,008 shares during the period. Shaker Investments LLC OH’s holdings in Medpace were worth $251,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Pallas Capital Advisors LLC grew its position in Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after acquiring an additional 2,101 shares in the last quarter. Baillie Gifford & Co. grew its holdings in shares of Medpace by 175.6% in the third quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after purchasing an additional 9,478 shares in the last quarter. Barclays PLC increased its stake in Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after buying an additional 8,275 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in Medpace by 6.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after buying an additional 2,675 shares in the last quarter. Finally, CWA Asset Management Group LLC purchased a new position in Medpace in the 3rd quarter valued at approximately $1,306,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of MEDP opened at $354.51 on Tuesday. The firm has a fifty day moving average price of $343.88 and a 200 day moving average price of $349.52. The stock has a market cap of $11.02 billion, a PE ratio of 31.04, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. As a group, equities analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. TD Cowen decreased their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, Truist Financial decreased their price target on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.